Literature DB >> 26422625

Oral or intravenous iron for anemia correction in chronic kidney disease?

Tilman B Drüeke1, Ziad A Massy1,2.   

Abstract

Iron deficiency in patients with chronic kidney disease (CKD) can be corrected by the oral or intravenous route. The natural intestinal barrier against iron overload is circumvented by intravenous iron. The balance between benefit and risk of high iron doses remains unclear. In a randomized controlled trial in CKD patients, Agarwal et al. find similar effects of oral and intravenous iron on hemoglobin levels and kidney function decline but more serious cardiovascular events and infections with intravenous iron.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26422625     DOI： 10.1038/ki.2015.189

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  9 in total

1.  Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.

Authors:  Antonio Pisani; Eleonora Riccio; Massimo Sabbatini; Michele Andreucci; Antonio Del Rio; Bianca Visciano
Journal:  Nephrol Dial Transplant       Date:  2014-11-13       Impact factor: 5.992

Review 2.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

3.  Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.

Authors:  George R Bailie; Maria Larkina; David A Goodkin; Yun Li; Ronald L Pisoni; Brian Bieber; Nancy Mason; Lin Tong; Francesco Locatelli; Mark R Marshall; Masaaki Inaba; Bruce M Robinson
Journal:  Kidney Int       Date:  2014-07-30       Impact factor: 10.612

4.  Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Jia-Sin Liu; Yu-Kang Chang; Chih-Cheng Hsu; Der-Cherng Tarng
Journal:  Nephrol Dial Transplant       Date:  2015-03-31       Impact factor: 5.992

5.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

Review 6.  Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.

Authors:  Benaya Rozen-Zvi; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici; Ofer Shpilberg; Uzi Gafter
Journal:  Am J Kidney Dis       Date:  2008-10-08       Impact factor: 8.860

7.  A randomized trial of intravenous and oral iron in chronic kidney disease.

Authors:  Rajiv Agarwal; John W Kusek; Maria K Pappas
Journal:  Kidney Int       Date:  2015-06-17       Impact factor: 10.612

8.  The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

Authors:  Piotr Ponikowski; Gerasimos Filippatos; Josep Comin Colet; Ronnie Willenheimer; Kenneth Dickstein; Thomas Lüscher; Giedrius Gaudesius; Barbara von Eisenhart Rothe; Claudio Mori; Nicola Greenlaw; Ian Ford; Iain Macdougall; Stefan D Anker
Journal:  Eur J Heart Fail       Date:  2015-02-11       Impact factor: 15.534

9.  FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

Authors:  Iain C Macdougall; Andreas H Bock; Fernando Carrera; Kai-Uwe Eckardt; Carlo Gaillard; David Van Wyck; Bernard Roubert; Jacqueline G Nolen; Simon D Roger
Journal:  Nephrol Dial Transplant       Date:  2014-06-02       Impact factor: 5.992
  9 in total
  4 in total

Review 1.  Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment.

Authors:  Elizabeth Katherine Batchelor; Pinelopi Kapitsinou; Pablo E Pergola; Csaba P Kovesdy; Diana I Jalal
Journal:  J Am Soc Nephrol       Date:  2020-02-10       Impact factor: 10.121

2.  Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.

Authors:  Luigi Cirillo; Chiara Somma; Marco Allinovi; Alfredo Bagalà; Giuseppe Ferro; Elio Di Marcantonio; Stefania Bellelli; Lorenzo Antonio Dallari; Piercarlo Ballo; Pietro Claudio Dattolo
Journal:  Sci Rep       Date:  2021-04-02       Impact factor: 4.379

Review 3.  Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.

Authors:  Guy Rostoker; Nosratola D Vaziri; Steven Fishbane
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

4.  Predictors of poor health-related quality of life among hemodialysis patients with anemia in Jordan.

Authors:  Osama Y Alshogran; Esraa A Shatnawi; Shoroq M Altawalbeh; Anan S Jarab; Randa I Farah
Journal:  Health Qual Life Outcomes       Date:  2021-12-24       Impact factor: 3.186
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.